Microbial Messengers of Pain: Examining the Impact of the Gut Microbiota on TMJ Inflammation and Dysfunction

Yashika Singh Mudhai[1]
[1]Manipal College of Dental Sciences, Madhav Nagar, Eshwar Nagar, Manipal, Karnataka - 576104

Corresponding Author
Yashika Singh Mudhai
E-mail ID : mudhaiyashika16@gmail.com

Submission:09.02.2025 Acceptance:09.04.2025 Publication:30.06.2025
https://www.doi.org/1063778/CJID-DRJPL/2025-569

Introduction

Temporomandibular Joint Disorders (TMJD) have a substantial impact on the musculoskeletal and neurological systems, disturbing the lives of many patients who frequently complain of chronic TMJ pain. However, there are currently insufficient therapy options for TMDs. Inflammatory TMD pain is commonly treated with nonsteroidal anti-inflammatory medications[1, 2]. Finding a suitable treatment for TMJ-related pain may be made easier by recent research on the impact of gut microbiota and epigenetic variables. Prior research suggests that TMD and IBS are related [3]. The etiology, frequency, and severity of TMD and IBS (Inflammatory Bowel Syndrome) were compared in this scoping review, along with any possible parallels in the ways that the neurological and endocrine systems affect both. We also talk about the possible connection between gender predisposition and suffering. Furthermore, we go over the most recent non-invasive treatment alternatives that have been proposed for the treatment of TMJ and orofacial pain.

Methods

Articles from PubMed, National Library of Medicine and Research Gate were retrieved using the search terms (“GM” OR “gut microbiome” OR “gut bacteria” OR “probiotics” OR “prebiotics”) “metabolites”[4] AND (“orofacial pain”). Articles written only in English, randomized control trials, quasi-randomized control trials, and in-vitro (laboratory) and in-vivo studies were the requirements for admission. research, both prospective and retrospective, cohort studies. To get a definitive study to comprehend the relationship between the gut microbiota and TMDs, 20 articles were read and scanned. Additionally, based on the examination of all cited articles, gender disposition and non-invasive advancements were also covered.

Results

We observe growing evidence that chronic orofacial discomfort, particularly TMJ disorders, is strongly associated with gut microbiota (GM). Short-chain fatty acids (SCFAs), neurotransmitters (dopamine, serotonin), and amino acid byproducts are metabolites derived from genetically modified organisms (GM) that affect nociceptor activation and pain signaling through both immunological and neurological (vagus nerve) pathways.[5][4] Research indicates that gut dysbiosis affects glial cells, which are important for the transmission of pain. Chronic pain and visceral hypersensitivity are exacerbated by neuroinflammation brought on by glial activation. According to animal research, treatments such as vitamin B, photobiomodulation, resveratrol[2], and berberine[6] are useful in lowering microglial inflammation and glial activation, which in turn lessens pain.TMJ issues are more common in those with gastrointestinal conditions including GERD and IBS, according to clinical study. These intestinal disorders change the makeup of microorganisms and the release of metabolites.

Probiotics, gluten-free diets, omega-3 fatty acids, resveratrol, melatonin, and microbiome engineering are examples of therapeutic innovations that concentrate on non-invasive gut regulation. The results of these treatments for chronic orofacial pain are improved, neuroinflammation is decreased, and microbial balance is restored. Variations in GM composition influenced by hormones and the use of contraceptives are also linked to gender differences in pain perception, indicating the possibility of gender-specific, microbiome-targeted pain treatments. All things considered, addressing gut microbiota presents a fresh, innovative, and non-invasive strategy for treating persistent orofacial and TMJ pain.

Discussion

Worldwide, IBS and TMJ disorders are have important implications on the overall health of people. Both are considered as non-communicable diseases that share a common risk factor (unhealthy eating behavior and high carbohydrate intake); however, from a holistic perspective, the relationship between these conditions may not be simple. According to a research by Gallotta et.al., IBS patients had a TMD risk more than three times greater than Healthy controls.[7]

IBS affects 11% of people worldwide, and women are two to three times more likely than males to experience the symptoms, with the majority receiving a diagnosis before the

age of 45. Likewise, TMD is a type of common maxillofacial ailment that is most frequently observed in young to middle-aged people (20 to 50 years old), with a peak incidence around 20 to 40 years old.[8,9] . According to a 2018 meta-analysis, women were 2.2 times more likely than men to present with TMD.[10] The majority of women with TMD are teens and young adults, in contrast to similar joint illnesses that also have a higher female preference but occur after menopause.[11] The reasons for this marked sexual dimorphism and age distribution remain unclear. It is estimated that the differences might be related to hormonal factors (particularly estrogen). Female TMD patients had a longer duration of disease before seeking care and higher average age than males. Females were more likely to have limitations in jaw movement than males.[12]

Gut microbial dysbiosis is common in individuals experiencing chronic pain, restoring the makeup and function of the gut microbiome significantly reduces that nature of pain.[13,14,15] It has been shown that alterations in gut microbiota composition and microbial metabolites are vital factors affecting the host nociceptive and inflammatory responses mediated by microglia in the central nervous system (CNS).[16,17] Data and research on the correlation between TMDs and IBS is scarce. Korszun et al, in 1998, reported TMJ related issues in 46% of 39 total patients who had overlapping IBS. Another recent prospective cohort studies research was conducted by Sanders et al[18] in 2013 in multisite OPPERA designed to understand the etiology of first-onset TMD and variation in its genetic, biological and psychosocial determinants. Large sample size and rigorous methodology demonstrated that incidence of first onset TMD was 3 times higher in people with IBS on enrolment as in people without IBS. Patients with both IBS and TMD report high pain sensitivity[19] and also demonstrate reduced pain inhibition, probably because of dysfunction of endogenous pain inhibition systems aligning with the theory of a generalized upregulation of pain processing in chronic pain conditions.[20] These findings suggest a shared pathophysiological basis involving gut dysbiosis and neuroimmune interactions, highlighting the need for integrated diagnostic and therapeutic strategies that consider the gut-brain-joint axis in managing chronic orofacial pain.

In conclusion, the association between gut microbiota dysregulation and chronic orofacial conditions such as TMD underscores the importance of a systems biology approach in clinical evaluation. Multisystem pain syndromes may have a primary channel through the gut-brain axis, which is influenced by immunological activity, microbial metabolites, and hormonal control. Both IBS and TMD exhibit a strong gender propensity, which suggests a complicated interaction between immune regulation, sex hormones, and microbiome composition. The idea that gut health therapies, including probiotics, dietary modifications, and lifestyle changes, may provide a potential adjunct in the management of chronic orofacial pain is consistently supported by the available data, despite its limitations. In order to establish causality, find microbial markers of disease, and evaluate treatments that target the microbiome, future research should concentrate on longitudinal and interventional investigations. To improve patient outcomes in this new paradigm, a multidisciplinary and precision medicine strategy combining pain management, dental, gastrointestinal, and microbiome science is crucial.

Source of Support: Nil

Conflict of Interest: Nil

Reference

1. D. R. Ta LE, "Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen," The journal of the International Association for the Study of Pain, vol. 111, no. 1, pp. 13-21, 2004.
2. Ma Y, Liu S Department of Biomedical Sciences, Texas A&M University College of Dentistry, Dallas, TX, USA, "Resveratrol alleviates temporomandibular joint inflammatory pain by recovering disturbed gut microbiota.," PubMed Central, no. 87, p. 455–464, 2020.
3. Saczuk K., Rozuk S. Medical University of Lodz: Łódź, PL, "Association Between Temporomandibular Disorders and Irritable bowel Syndrome- A Scoping Review," Journal of Clinical Medicine, no. 13, 2024.
4. C. D. B. S. Milshteyn A, "Accessing Bioactive Natural Products from the Human Microbiome.," Cell Host Microbe, no. 23, pp. 725-736, 2018.
5. L. J. e. al, "Functions of Gut Microbiota Metabolites, Current Status and Future Perspectives," Aging and disease, vol. 4, no. 13, p. 1106–1126, 2022.
6. Z. L. e. al, "Effects of Berberine on the Gastrointestinal Microbiota," Frontiers, vol. 10, 2020.
7. G. S. e. al, "High risk of temporomandibular disorder in irritable bowel syndrome: Is there a correlation with greater illness severity?," World J Gastroenterol., vol. 23, no. 1, pp. 103-109, 2017.

8. J. R. List T, "Temporomandibular disorders: old ideas and new concepts.," Cephalgia, vol. 37, no. 7, pp. 692-704, 2017.
9. G.-N. L. W. E. P. F. A. J. L. F. Manfredini D, "Research diagnostic criteria for temporomandibular disorders: a systematic review of axis I epidemiologic findings," Oral Surg Oral Med Oral Pathol Oral Radiol Endod., vol. 4, no. 112, pp. 453-462, 2011.
10. Z. W. A. G. L. M. C. V. Rentsch M, "Prevalence of temporomandibular disorders based on a shortened symptom questionnaire of the diagnostic criteria for temporomandibular disorders and its screening reliability for children and adolescents aged 7–14 years.," J Clin Med., vol. 12, no. 12, 2023.
11. X. X. L. S. e. a. Yu S, "Locally synthesized estrogen plays an important role in the development of TMD.," Med Hypotheses, vol. 6, no. 72, pp. 720-722, 2009.
12. H. Q. e. al, "Clinical profile in relation to age and gender of patients with temporomandibular disorders: a retrospective study," BMC Oral Health, 2024.
13. S. L. H. K. Z. J. Aamodt A, "Comorbidity of headache and gastrointestinal complaints.The Head-HUNT Study. Cephalalgia," Sage Journals, no. 28, pp. 144-151, 2008.
14. G. E. B. N. A. A. D. K. F. M.-A. C. S. S. Y. Minerbi A, "Altered microbiome composition in individuals with fibromyalgia. Pain.," The Journal of International Association for the Study of Pain, no. 160, pp. 2589-2602, 2019.
15. F. C. G. A. L. J. S. S. D. G. B. R. D. M. V. D. A. H. Schott EM, "Targeting the gut microbiome to treat the osteoarthritis of obesity.," JCI Insight, vol. 3, no. 8, 2018.
16. Erny, "Host microbiota constantly control maturation and function of microglia in the CNS.," Nat Neurosci, vol. 7, no. 18, 2015.
17. E. D. e. al, "Communicating systems in the body: how microbiota and microglia cooperate," Immunology , vol. 1, no. 150, pp. 7-15, 2017.
18. S. A. e. al, "General health status and incidence of first-onset temporomandibular disorder: the OPPERA prospective cohort study.," J. Pain, no. 14, pp. 151-162, 2013.
19. G. J. e. al, "Pain sensitivity risk factors for chronic TMD: descriptive data and empirically identified domains from the OPPERA case control study.," J. Pain, no. 12, pp. 61-74, 2011.
20. K. C. e. al, "Deficiency in endogenous modulation of prolonged heat pain in patients with Irritable Bowel Syndrome and Temporomandibular Disorder," Pain, no. 143, pp. 172-178, 2009.
21. K. F. e. al, "Temporomandibular disorders: a review of current concepts in," Oral Surgery, Author Manuscript, no. 13, pp. 331-334, 2020.
22. M. D. G. M. Melis, "The role of genetic factors in the etiology of temporomandibular disorders: a review," Cranio : the journal of craniomandibular practice, pp. 43-51, 2016.
23. N. A. B. D. Krishnamoorthy G., "The gut-masticatory muscles-temporomandibular joint pain axis—a scoping review," Journal of Oral & Facial Pain and Headache, vol. 1, no. 39, pp. 24-33, 2025.